The United States has announced the launch of the world's first drug aimed at slowing the progression of Alzheimer's disease, CBC News reports.
The US Food and Drug Administration has granted full approval for the production of the drug, which not only addresses the symptoms but also slows down the advancement of the disease. Developed by Eisai and Biogen, the drug known as Leqembi has demonstrated the ability to slow the decline of memory and cognitive function.
The initial approval of the drug in January was based on the findings of a study involving 800 individuals exhibiting early signs of Alzheimer's. Subsequently, the drug underwent a comprehensive approval process based on the results of a larger study involving 1,800 patients.
While Leqembi offers hope for patients, it does come with certain limitations. The drug requires bi-monthly infusions and may have side effects such as brain swelling, infusion-related reactions, and headaches, according to the Alzheimer's Association.
The cost of treatment with Leqembi is estimated at $26,500 per year, posing a financial burden for economically disadvantaged patients.
Alzheimer's disease, the most common form of dementia characterized by a decline in mental abilities due to brain damage, affects memory, thinking, and behavior.
It is projected that by 2022, the number of people affected by Alzheimer's globally will reach 55mn, with expectations of nearly doubling every two decades. By 2030, it is anticipated to rise to 78mn and by 2050, to 139mn individuals.
Comments (0)